- Condition: Major Depressive Disorder
Interventions: Drug: Placebo; Drug: Vilazodone; Drug: Vilazodone
Sponsors: Forest Laboratories; Forest Laboratories
Recruiting - verified April 2012 - Conditions: Unipolar Depression; Bipolar Depression
Interventions: Device: Sham tDCS device; Device: Soterix tDCS device
Sponsors: The University of New South Wales; The University of New South Wales; Duke University; Emory University; Sheppard Pratt Health System; University of Medicine and Dentistry New Jersey; University of Texas
Not yet recruiting - verified March 2012 - Condition: Major Depressive Disorder
Interventions: Drug: AZD6765 iv; Drug: AZD6765 iv; Drug: Placebo
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified February 2012 - Condition: Acute Depressive Episode
Interventions: Drug: Ramelteon SL; Drug: Ramelteon SL; Drug: Ramelteon SL; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2012 - Condition: Major Depressive Disorder
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate ); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2012 - Conditions: Major Depressive Disorder; Attention-deficit Hyperactivity Disorder (ADHD)
Intervention:
Sponsors: Wake Forest University Baptist Medical Center; Wake Forest University Baptist Medical Center
Recruiting - verified September 2011 - Condition: Major Depressive Disorder
Intervention: Drug: Lurasidone
Sponsors: Sunovion; Sunovion
Recruiting - verified April 2012 - Condition: Major Depressive Disorder
Interventions: Drug: Lurasidone 20 mg; Drug: Lurasidone 60 mg; Drug: Placebo
Sponsors: Sunovion; Sunovion
Not yet recruiting - verified November 2011 - Condition: Major Depressive Disorder With Mixed Features
Interventions: Drug: Lurasidone; Drug: Placebo
Sponsors: Sunovion; Sunovion
Recruiting - verified April 2012 - Conditions: Breast Cancer; Cognitive/Functional Effects; Depression; Fatigue; Pain; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Skin Reactions Secondary to Radiation Therapy
Interventions: Genetic: DNA analysis; Genetic: gene expression analysis; Other: enzyme-linked immunosorbent assay; Other: flow cytometry; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: adjuvant therapy; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment; Radiation: 3-dimensional conformal radiation therapy; Radiation: breast irradiation; Radiation: external beam radiation therapy; Radiation: hypofractionated radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: whole breast irradiation
Sponsors: National Cancer Institute (NCI); Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Depression, Bipolar
Interventions: Drug: Placebo; Drug: Cariprazine; Drug: Cariprazine; Drug: Cariprazine
Sponsors: Forest Laboratories; Forest Laboratories; Gedeon Richter Ltd.
Recruiting - verified March 2012 - Conditions: Depression; HIV
Intervention: Other: Measurement-Based Care collaborative depression management
Sponsors: Duke University; Duke University; National Institute of Mental Health (NIMH); University of North Carolina, Chapel Hill; University of Alabama at Birmingham
Recruiting - verified June 2011 - Condition: Major Depressive Disorder
Interventions: Drug: desvenlafaxine succinate sustained release; Drug: fluoxetine; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Major Depressive Disorder
Intervention: Drug: DVS SR
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Major Depressive Disorder
Interventions: Device: NEST-1 (NeoSync EEG Synchronized TMS); Device: SHAM
Sponsors: NeoSync, Inc.; NeoSync, Inc.
Recruiting - verified May 2012 - Condition: Depression
Interventions: Drug: Duloxetine; Drug: Escitalopram; Drug: BMS-820836 Placebo; Drug: BMS-820836; Drug: BMS-820836; Drug: BMS-820836; Drug: BMS-820836
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified August 2011 - Condition: Cancer
Interventions: Drug: prasterone; Other: placebo
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Depression
Interventions: Drug: Placebo matching with BMS-820836; Drug: BMS-820836; Drug: BMS-820836; Drug: BMS-820836
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified July 2011 - Conditions: Depressive Disorder; Depression; Depressive Disorder, Major; Mood Disorders; Mental Disorders
Interventions: Drug: OPC-34712 + ADT; Drug: Placebo + ADT; Drug: Placebo + ADT
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified July 2011 - Conditions: Perimenopause; Menopause; Depression
Intervention: Drug: Estradiol
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; National Institute of Mental Health (NIMH)
Recruiting - verified February 2012 - Condition: Depression
Interventions: Drug: Armodafinil; Drug: Placebo
Sponsors: Teva Pharmaceutical Industries; Cephalon
Recruiting - verified May 2012 - Condition: Major Depressive Disorder
Interventions: Drug: LY2216684; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Depression
Interventions: Drug: Duloxetine; Drug: Placebo matching with BMS-820836; Drug: BMS-820836; Drug: Duloxetine; Drug: Placebo matching with Duloxetine
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Conditions: Breast Cancer; Depression; Fatigue; Sleep Disorders
Interventions: Drug: metformin hydrochloride; Genetic: DNA analysis; Genetic: RNA analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Bipolar
Interventions: Drug: Lurasidone; Drug: Placebo
Sponsors: Sunovion; Sunovion
Recruiting - verified April 2012 - Condition: Treatment Resistant Depression
Interventions: Drug: CX157; Drug: Placebo
Sponsors: CeNeRx BioPharma Inc.; CeNeRx BioPharma Inc.
Recruiting - verified October 2011 - Conditions: Infant, Newborn; Hypoxia, Brain; Hypoxia-Ischemia, Brain; Encephalopathy, Hypoxic-Ischemic; Hypoxic-Ischemic Encephalopathy; Ischemic-Hypoxic Encephalopathy
Intervention: Procedure: Whole-body Cooling
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR)
Recruiting - verified February 2012 - Conditions: Depression; Bipolar
Interventions: Drug: ziprasidone; Drug: Sugar pill
Sponsors: Tufts Medical Center; Tufts Medical Center; Duke University; University of South Carolina
Recruiting - verified July 2011 - Condition: Depression
Intervention: Drug: Armodafinil
Sponsors: Teva Pharmaceutical Industries; Cephalon
Recruiting - verified May 2012 - Stepped Enhancement of PTSD Services Using Primary Care (STEPS UP): A Randomized Effectiveness TrialConditions: Posttraumatic Stress Disorder (PTSD); Depression
Interventions: Behavioral: STEPS UP; Behavioral: OUC
Sponsors: Henry M. Jackson Foundation for the Advancement of Military Medicine; Henry M. Jackson Foundation for the Advancement of Military Medicine; Department of Defense; RAND; RTI International
Recruiting - verified March 2012 - Condition: Depression
Interventions: Drug: lithium and Venlafaxine; Procedure: ECT
Sponsors: Mount Sinai School of Medicine; Mount Sinai School of Medicine; National Institute of Mental Health (NIMH)
Recruiting - verified March 2012 - Condition: Coronary Heart Disease
Interventions: Behavioral: SMT-enhanced Cardiac Rehabilitation; Behavioral: Standard Cardiac Rehabilitation
Sponsors: Duke University; Duke University; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2012 - Conditions: Cancer Survivor; Depression; Gastrointestinal Complications; Male Erectile Disorder; Prostate Cancer; Psychosocial Effects of Cancer and Its Treatment; Urinary Complications
Interventions: Behavioral: telephone-based intervention; Other: educational intervention; Other: partner-assisted coping skills training; Other: questionnaire administration; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: East Carolina University; East Carolina University; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Bipolar; Depression
Intervention: Drug: lurasidone
Sponsors: Sunovion; Sunovion
Recruiting - verified April 2012 - Condition: Major Depressive Disorder
Interventions: Drug: Escitalopram; Drug: Sertraline; Drug: Venlafaxine XR
Sponsors: BRC Operations Pty. Ltd.; BRC Operations Pty. Ltd.
Recruiting - verified March 2012 - Conditions: Psychotic Depression; Major Depression With Psychotic Features; Psychosis
Interventions: Drug: mifepristone; Drug: placebo
Sponsors: Corcept Therapeutics; Corcept Therapeutics
Recruiting - verified February 2012 - Conditions: Infant, Newborn; Hypoxia, Brain; Hypoxia-Ischemia, Brain; Encephalopathy, Hypoxic-Ischemic; Hypoxic-Ischemic Encephalopathy; Ischemic-Hypoxic Encephalopathy
Interventions: Procedure: Hypothermia; Procedure: Normothermic Control
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR)
Recruiting - verified September 2011 - Conditions: Bipolar Disorder; Bipolar Depression
Interventions: Drug: citalopram + mood stabilizer; Procedure: FDG PET scans; Procedure: MRI structural scans; Procedure: Genotyping; Procedure: Blood Draw; Drug: placebo + mood stabilizer
Sponsors: Tufts Medical Center; Tufts Medical Center; National Institute of Mental Health (NIMH)
Recruiting - verified July 2011 - Condition: Depression
Interventions: Device: Thymatron; Device: Magstim Theta
Sponsors: New York State Psychiatric Institute; New York State Psychiatric Institute; Duke University; University of Texas Southwestern Medical Center; Stanley Medical Research Institute
Recruiting - verified December 2011
 |
Join Clinical Trials in North Carolina for Depression |
